ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,350.30
0.06%
US Tech 100
18,579.00
0.33%
Dow Jones
38,740.29
-0.15%
Brent Oil
81.375
2.56%
Bitcoin
69,868.01
0.31%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Immunome Inc (IMNM)

  7. Immunome Inc (IMNM) News

IMNM

Immunome (IMNM)

Immunome Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IMNM
DateTimeSourceHeadlineSymbolCompany
05/20/20248:00AMBusiness WireImmunome Announces Completion of Purchase of Assets from AtrecaNASDAQ:IMNMImmunome Inc
05/17/20245:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
05/17/20248:00AMBusiness WireImmunome Announces Promotion of Max Rosett to Chief Financial OfficerNASDAQ:IMNMImmunome Inc
05/14/20248:48AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMNMImmunome Inc
05/14/20248:05AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMNMImmunome Inc
05/14/20248:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNMImmunome Inc
05/14/20248:00AMBusiness WireImmunome Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IMNMImmunome Inc
05/08/20248:00AMBusiness WireImmunome to Present at 2024 Bank of America Healthcare ConferenceNASDAQ:IMNMImmunome Inc
05/02/20248:00AMBusiness WireImmunome Appoints Kinney Horn as Chief Business OfficerNASDAQ:IMNMImmunome Inc
04/25/20248:26AMBusiness WireImmunome Appoints Sandra M. Swain to Board of DirectorsNASDAQ:IMNMImmunome Inc
04/05/20248:00AMBusiness WireImmunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:IMNMImmunome Inc
03/28/20244:02PMBusiness WireImmunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired AssetsNASDAQ:IMNMImmunome Inc
03/26/20248:00AMBusiness WireImmunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From AyalaNASDAQ:IMNMImmunome Inc
03/07/20248:00AMBusiness WireImmunome to Participate in the Leerink Partners Global Biopharma ConferenceNASDAQ:IMNMImmunome Inc
03/01/20248:00AMBusiness WireImmunome to Participate in the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:IMNMImmunome Inc
02/21/20249:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
02/21/20249:07PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
02/20/20248:15AMBusiness WireImmunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsNASDAQ:IMNMImmunome Inc
02/16/20244:05PMBusiness WireImmunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:IMNMImmunome Inc
02/14/20244:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNMImmunome Inc
02/14/20244:09PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMNMImmunome Inc
02/13/202410:38PMBusiness WireImmunome Announces Pricing of Public Offering of Common StockNASDAQ:IMNMImmunome Inc
02/13/20244:36PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMNMImmunome Inc
02/13/20244:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNMImmunome Inc
02/13/20244:05PMBusiness WireImmunome Announces Proposed Public Offering of Common StockNASDAQ:IMNMImmunome Inc
02/12/20242:10PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMNMImmunome Inc
02/06/20248:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNMImmunome Inc
02/05/20248:00AMBusiness WireImmunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:IMNMImmunome Inc
02/02/20244:04PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IMNMImmunome Inc
01/31/20248:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
 Showing the most relevant articles for your search:NASDAQ:IMNM

Your Recent History

USOTC
PSRU
Valiant Eagle (PK)
USOTC
SMCE
SMC Entertainment (PK)
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
NSAV
Net Savings Link (PK)
USOTC
BLEG
Branded Legacy (PK)
USOTC
CYDY
CytoDyn (QB)
USOTC
CGAC
Code Green Apparel (PK)
USOTC
FMCC
Federal Home Loan Mortgage (QB)
USOTC
FNMA
Fannie Mae (QB)
USOTC
BLLB
Bell Buckle (PK)
NASDAQ
DJT
Trump Media and Technology
USOTC
HQGE
HQ Global Education (CE)
USOTC
XERI
Xeriant (QB)
NASDAQ
AGBA
AGBA
NASDAQ
FCEL
FuelCell Energy
USOTC
AFFU
Affluence (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved